Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

Also called NCT01990469

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 219 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01990469
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01990469. Randomized; quadruple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
Condition
T2DM
Intervention (Drug)
Gemigliptin
Intervention (Drug)
Gemigliptin placebo
Lead sponsor
LG Life Sciences (class: industry)

Record details

Record id
cardio:ct-nct01990469
Content hash
6cb8338d650471f2a4e7f040fa86b21cae189019f971e7fc7c873f1bb0a9dc82